Livzon Pharmaceutical Group Inc. Stock

Equities

000513

CNE0000002Y8

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-11 pm EDT 5-day change 1st Jan Change
36.89 CNY -0.54% Intraday chart for Livzon Pharmaceutical Group Inc. -1.10% +5.37%
Sales 2024 * 13.22B 1.83B Sales 2025 * 14.57B 2.01B Capitalization 29.82B 4.12B
Net income 2024 * 2.18B 301M Net income 2025 * 2.45B 338M EV / Sales 2024 * 1.76 x
Net cash position 2024 * 6.51B 899M Net cash position 2025 * 5.17B 715M EV / Sales 2025 * 1.69 x
P/E ratio 2024 *
15.7 x
P/E ratio 2025 *
13.9 x
Employees 8,933
Yield 2024 *
4.52%
Yield 2025 *
5.07%
Free-Float 38.38%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024. CI
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2% MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024 CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug MT
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration CI
Livzon Pharma Gets Nod to Trial Weight Management Drug MT
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President MT
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023. CI
Livzon Pharma Recognizes Credit, Asset Impairments MT
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical MT
Livzon Pharmaceutical Shareholders to Vote on Spin-Off, Separate Listing of Livzon Diagnostics MT
Livzon Pharma's 190 Products Added to China's National Reimbursement Drug List MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use MT
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use CI
More news
1 day-0.54%
1 week-1.10%
Current month+1.07%
1 month-4.97%
3 months+3.89%
6 months+2.19%
Current year+5.37%
More quotes
1 week
36.08
Extreme 36.08
37.59
1 month
35.31
Extreme 35.31
39.61
Current year
32.70
Extreme 32.7
39.93
1 year
31.72
Extreme 31.72
40.58
3 years
28.88
Extreme 28.88
57.50
5 years
22.15
Extreme 22.1538
62.20
10 years
14.08
Extreme 14.0751
62.20
More quotes
Managers TitleAgeSince
President 55 18-07-16
Director of Finance/CFO 56 93-03-31
Chairman 59 00-12-31
Members of the board TitleAgeSince
Chairman 62 01-12-31
Director/Board Member 53 07-03-31
Director/Board Member 53 13-05-31
More insiders
Date Price Change Volume
24-04-12 36.89 -0.54% 3,052,155
24-04-11 37.09 +1.62% 4,814,768
24-04-10 36.5 -1.22% 4,451,755
24-04-09 36.95 -0.24% 6,760,319
24-04-08 37.04 -0.70% 6,114,897

End-of-day quote Shenzhen S.E., April 11, 2024

More quotes
LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
36.89 CNY
Average target price
41.05 CNY
Spread / Average Target
+11.27%
Consensus
  1. Stock Market
  2. Equities
  3. 000513 Stock